Medicago Announces Positive Results of Trials for its COVID-19 Vaccine Candidate |
|
|
|
Biopharmaceutical company Medicago announced on May 14, 2020, that its vaccine candidate for COVID-19 induced a positive antibody response only 10 days after a single dose in mice. In early March, the company produced a Virus-Like Particle (VLP) of the coronavirus just 20 days after obtaining the SARS-CoV-2 genome sequence and quickly initiated pre-clinical testing. Medicago uses proprietary plant-based technology to develop protein-based therapeutics. Instead of traditional vaccine development, the company uses VLPs that mimic the shape and dimensions of a virus.
|
|
|
|
|
|
|
|
|
ISAAA Monitors Progress of Research on COVID-19 |
|
|
|
ISAAA is monitoring the progress of research on COVID-19 treatments using plant-based technologies such as genetic engineering and genome editing, as well as other related techniques. We also keep track of the pandemic's effect on food security and agriculture. This is our effort to provide science-based information that can help the public make decisions and actions to mitigate and recover from the impact of COVID-19. We have summarized all publications and articles related to COVID-19 in the COVID-19 Resource page of the ISAAA website.
|
|
|
|
|
|
|
|
A biweekly update on genome editing research, regulations, and impact
produced by ISAAA Inc. |
| |
|
|
|
| A monthly update on gene drive research and development provided by ISAAA in collaboration with the Outreach Network for Gene Drive Research |
| |
|
|
|
|
GM APPROVAL UPDATES |
- Brazil approved the wheat event HB4 for commercial cultivation.
- The Philippines approved the eggplant event EE-1 for cultivation
- The USA approved the canola event MON94100 for food and feed.
- Nigeria approved the wheat event HB4 for food and feed.
- The USA approved the corn event MON87429 for food and feed.
- Ghana approved the cowpea event AAT709A for food, feed, and cultivation.
|
|
|
|
| Biotech Updates is a weekly newsletter of ISAAA, a not-for-profit organization. It is distributed for free to over 22,000 subscribers worldwide to inform them about the key developments in biosciences, especially in biotechnology. Your support will help us in our mission to feed the world with knowledge. You can help by donating as little as $10. |
|
|
|
|
